ADAR antibody (AA 151-250)

Catalog No. ABIN678218

Product Details anti-ADAR Antibody

Target: ADAR (Adenosine Deaminase, RNA-Specific (ADAR))

Binding Specificity: AA 151-250

Reactivity: Human

Host: Rabbit

Clonality: Polyclonal

Conjugate: This ADAR antibody is un-conjugated

Application: Western Blotting (WB), ELISA, Immunofluorescence (Cultured Cells) (IF (cc)), Immunofluorescence (Paraffin-embedded Sections) (IF (p)), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Immunohistochemistry (Frozen Sections) (IHC (fro))

Cross-Reactivity: Human

Purification: Purified by Protein A.

Immunogen: KLH conjugated synthetic peptide derived from human ADAR1

Isotype: IgG

Application Details

Application Notes: WB 1:300-5000
ELISA 1:500-1000
IHC-P 1:200-400
IHC-F 1:100-500
IF(IHC-P) 1:50-200
IF(IHC-F) 1:50-200
IF(ICC) 1:50-200

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: 1 μg/μL

Buffer: 0.01M TBS( pH 7.4) with 1 % BSA, 0.02 % Proclin300 and 50 % Glycerol.

Preservative: ProClin

Precaution of Use: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.

Storage: 4 °C,-20 °C

Storage Comment: Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.

Expiry Date: 12 months

Target Details for ADAR

Target: ADAR (Adenosine Deaminase, RNA-Specific (ADAR))

Alternative Name: ADAR1 (ADAR Products)

Synonyms: red1 antibody, drada antibody, wu:fc22a02 antibody, adar1 antibody, dsRAD antibody, dsRAD-1 antibody, ADAR antibody, ADAR1 antibody, CG12598 antibody, Dmel\\CG12598 antibody, EG:BACN35H14.1 antibody, adar antibody, adr antibody, cg12598 antibody, dADAR antibody, dAdar antibody, hypnos-2 antibody, NV18763 antibody, AGS6 antibody, DRADA antibody, DSH antibody, DSRAD antibody, G1P1 antibody, IFI-4 antibody, IFI4 antibody, K88DSRBP antibody, P136 antibody, AV242451 antibody, Adar1 antibody, mZaADAR antibody, adenosine deaminase, RNA-specific antibody, adenosine deaminase, RNA-specific S homeolog antibody, adenosine deaminase, RNA specific antibody, Adenosine deaminase acting on RNA antibody, adenosine deaminase acting on RNA antibody, double-stranded RNA-specific editase 1 antibody, adar antibody, adar.S antibody, ADAR antibody, Adar antibody, CpipJ_CPIJ011849 antibody, LOC100114127 antibody

Background:

Synonyms: DSH, AGS6, G1P1, IFI4, P136, ADAR1, DRADA, DSRAD, IFI-4, K88DSRBP, Double-stranded RNA-specific adenosine deaminase, 136 kDa double-stranded RNA-binding protein, Interferon-inducible protein 4, ADAR

Background: Catalyzes the hydrolytic deamination of adenosine to inosine in double-stranded RNA (dsRNA) referred to as A-to-I RNA editing. This may affect gene expression and function in a number of ways that include mRNA translation by changing codons and hence the amino acid sequence of proteins, pre-mRNA splicing by altering splice site recognition sequences, RNA stability by changing sequences involved in nuclease recognition, genetic stability in the case of RNA virus genomes by changing sequences during viral RNA replication, and RNA structure-dependent activities such as microRNA production or targeting or protein-RNA interactions. Can edit both viral and cellular RNAs and can edit RNAs at multiple sites (hyper-editing) or at specific sites (site-specific editing). Its cellular RNA substrates include: bladder cancer-associated protein (BLCAP), neurotransmitter receptors for glutamate (GRIA2) and serotonin (HTR2C) and GABA receptor (GABRA3). Site-specific RNA editing of transcripts encoding these proteins results in amino acid substitutions which consequently alters their functional activities. Exhibits low-level editing at the GRIA2 Q/R site, but edits efficiently at the R/G site and HOTSPOT1. Its viral RNA substrates include: hepatitis C virus (HCV), vesicular stomatitis virus (VSV), measles virus (MV), hepatitis delta virus (HDV), and human immunodeficiency virus type 1 (HIV-1). Exhibits either a proviral (HDV, MV, VSV and HIV-1) or an antiviral effect (HCV) and this can be editing-dependent (HDV and HCV), editing-independent (VSV and MV) or both (HIV-1). Impairs HCV replication via RNA editing at multiple sites. Enhances the replication of MV, VSV and HIV-1 through an editing-independent mechanism via suppression of EIF2AK2/PKR activation and function. Stimulates both the release and infectivity of HIV-1 viral particles by an editing-dependent mechanism where it associates with viral RNAs and edits adenosines in the 5'UTR and the Rev and Tat coding sequence.

Gene ID: 103

UniProt: P55265

Pathways: Protein targeting to Nucleus